Literature DB >> 25673872

A nationwide survey of combined central and peripheral demyelination in Japan.

Hidenori Ogata1, Dai Matsuse1, Ryo Yamasaki2, Nobutoshi Kawamura3, Takuya Matsushita2, Tomomi Yonekawa1, Makoto Hirotani4, Hiroyuki Murai1, Jun-ichi Kira1.   

Abstract

OBJECTIVES: To clarify the clinical features of combined central and peripheral demyelination (CCPD) via a nationwide survey.
METHODS: The following characteristics were used to define CCPD: T2 high-signal intensity lesions in the brain, optic nerves or spinal cord on MRI, or abnormalities on visual-evoked potentials; conduction delay, conduction block, temporal dispersion or F-wave abnormalities suggesting demyelinating neuropathy based on nerve conduction studies; exclusion of secondary demyelination. We conducted a nationwide survey in 2012, sending questionnaires to 1332 adult and paediatric neurology institutions in Japan.
RESULTS: We collated 40 CCPD cases, including 29 women. Age at onset was 31.7±14.1 years (mean±SD). Sensory disturbance (94.9%), motor weakness (92.5%) and gait disturbance (79.5%) were common. Although cerebrospinal fluid protein levels were increased in 82.5%, oligoclonal IgG bands and elevated IgG indices were detected in 7.4% and 18.5% of cases, respectively. Fifteen of 21 patients (71.4%) had abnormal visual-evoked potentials. Antineurofascin 155 antibodies were positive in 5/11 (45.5%). Corticosteroids, intravenous immunoglobulins and plasmapheresis resulted in an 83.3%, 66.7% and 87.5% improvement, respectively, whereas interferon-β was effective in only 10% of cases. CCPD cases with simultaneous onset of central nervous system (CNS) and peripheral nervous system (PNS) involvement exhibited greater disability, but less recurrence and more frequent extensive cerebral and spinal cord MRI lesions compared to those with temporarily separated onset, whereas optic nerve involvement was more common in the latter.
CONCLUSIONS: CCPD shows different characteristics from classical demyelinating diseases, and distinctive features exist between cases with simultaneous and temporarily separated onset of CNS and PNS involvement. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  EPIDEMIOLOGY; MULTIPLE SCLEROSIS; NEUROIMMUNOLOGY; NEUROMUSCULAR; NEUROPATHY

Mesh:

Substances:

Year:  2015        PMID: 25673872     DOI: 10.1136/jnnp-2014-309831

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  20 in total

1.  From PNS to CNS: characteristics of anti-neurofascin 186 neuropathy in 16 cases.

Authors:  Chong Xie; Ze Wang; Nan Zhao; Desheng Zhu; Xiajun Zhou; Jie Ding; Yifan Wu; Haojun Yu; Yangtai Guan
Journal:  Neurol Sci       Date:  2021-03-15       Impact factor: 3.307

2.  Myelin oligodendrocyte glycoprotein-IgG-positive, steroid-responsive combined central and peripheral demyelination with recurrent peripheral neuropathy.

Authors:  Takaaki Nakamura; Kimihiko Kaneko; Genya Watanabe; Shogo Harashima; Emiko Kawasaki; Kenichi Tsukita; Toshiyuki Takahashi; Ichiro Nakashima; Tatsuro Misu; Yasushi Suzuki
Journal:  Neurol Sci       Date:  2020-10-19       Impact factor: 3.307

3.  Efficacy of rituximab as third-line therapy in combined central and peripheral demyelination.

Authors:  Salvatore Savasta; Thomas Foiadelli; Elisa Vegezzi; Andrea Cortese; Alessandro Lozza; Anna Pichiecchio; Diego Franciotta; Enrico Marchioni
Journal:  Neurol Clin Pract       Date:  2017-12

4.  Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy.

Authors:  Jérôme J Devaux; Yumako Miura; Yuki Fukami; Takayuki Inoue; Constance Manso; Maya Belghazi; Kenji Sekiguchi; Norito Kokubun; Hiroo Ichikawa; Anna Hiu Yi Wong; Nobuhiro Yuki
Journal:  Neurology       Date:  2016-02-03       Impact factor: 9.910

Review 5.  Neurofascin antibodies in chronic inflammatory demyelinating polyradiculoneuropathy: from intrinsic genetic background to clinical manifestations.

Authors:  Ze Wang; Xiajun Zhou; Nan Zhao; Chong Xie; Desheng Zhu; Yangtai Guan
Journal:  Neurol Sci       Date:  2021-03-29       Impact factor: 3.307

6.  Neurofascin-155 as a putative antigen in combined central and peripheral demyelination.

Authors:  Andrea Cortese; Jérôme J Devaux; Elisabetta Zardini; Constance Manso; Guillaume Taieb; Clarisse Carra Dallière; Philippe Merle; Cecilia Osera; Silvia Romagnolo; Nicolò Visigalli; Giuseppe Piscosquito; Ettore Salsano; Enrico Alfonsi; Arrigo Moglia; Davide Pareyson; Enrico Marchioni; Diego Franciotta
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-06-07

7.  Peripheral neuropathy in limbic encephalitis with anti-glutamate receptor antibodies: Case report and systematic literature review.

Authors:  Yi-Chia Wei; Chin-Chang Huang; Chi-Hung Liu; Hung-Chou Kuo; Jainn-Jim Lin
Journal:  Brain Behav       Date:  2017-08-01       Impact factor: 2.708

8.  Multifocal visual evoked potentials in chronic inflammatory demyelinating polyneuropathy.

Authors:  Jonas Graf; Lea Jansen; Jens Ingwersen; Marius Ringelstein; Jens Harmel; Jana Rybak; Robert Kolbe; Laura Rhöse; Lena Gemerzki; John-Ih Lee; Alexander Klistorner; Rainer Guthoff; Hans-Peter Hartung; Orhan Aktas; Philipp Albrecht
Journal:  Ann Clin Transl Neurol       Date:  2018-07-07       Impact factor: 4.511

Review 9.  Anti-Neurofascin 155 Antibody-Positive Chronic Inflammatory Demyelinating Polyneuropathy/Combined Central and Peripheral Demyelination: Strategies for Diagnosis and Treatment Based on the Disease Mechanism.

Authors:  Jun-Ichi Kira
Journal:  Front Neurol       Date:  2021-06-10       Impact factor: 4.003

Review 10.  Autoantibodies Against the Node of Ranvier in Seropositive Chronic Inflammatory Demyelinating Polyneuropathy: Diagnostic, Pathogenic, and Therapeutic Relevance.

Authors:  Atay Vural; Kathrin Doppler; Edgar Meinl
Journal:  Front Immunol       Date:  2018-05-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.